Use of CGM in Kidney Transplant Recipients
Launched by UNIVERSITY OF CALIFORNIA, DAVIS · Mar 3, 2021
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how continuous glucose monitoring (CGM) can help kidney transplant patients who have insulin-dependent Type 2 diabetes manage their blood sugar levels better. The goal is to see if using CGM helps these patients spend more time with their blood sugar in a healthy range, which is between 70 and 180 mg/dL.
To participate in this study, individuals need to be at least 18 years old, have received a kidney transplant within the past year, and have diabetes controlled with insulin. They should also have access to Wi-Fi at home, as this will be important for using the monitoring device. Participants will wear a CGM device that tracks their glucose levels and will need to check their blood sugar with a meter four times a day. This study is currently recruiting participants, and it’s important to note that certain people, such as those with Type 1 diabetes or those with serious health issues, will not be eligible to join. Overall, this trial aims to improve diabetes management for kidney transplant recipients, which could lead to better health outcomes for them.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 18 or above
- • 2. Received a kidney transplant within the past year with functioning kidney (eGFR \> 30 mL/min
- • 3. Person with Type 2 Diabetes and on insulin
- • 4. Access to home wi-fi connection
- Exclusion Criteria:
- • 1. Person with Type 1 Diabetes
- • 2. Patients taking hydroxyurea
- • 3. Patient unable to wear the Dexcom G6 device at all times for any reason
- • 4. Must be able to test blood glucose with meter 4x a day when on blinded CGM.
- • 5. Presence of clinically significant visual or cognitive impairment
- • 6. Illiterate
- • 7. Prisoners
- • 8. Women who are pregnant, who plan to become pregnant during the course of the study, or who are breastfeeding
- • 9. Presence of clinically unstable cardiovascular disease
- • 10. Active malignancy treatment
About University Of California, Davis
The University of California, Davis (UC Davis) is a leading research institution renowned for its commitment to advancing healthcare through innovative clinical trials and studies. With a strong focus on interdisciplinary collaboration, UC Davis leverages its extensive expertise in medical research, education, and patient care to drive breakthroughs in various fields, including medicine, public health, and agriculture. The university's clinical trial programs emphasize rigorous scientific methodology and ethical standards, aiming to translate research findings into impactful treatments and improved patient outcomes. Through its state-of-the-art facilities and a dedicated team of researchers and healthcare professionals, UC Davis is at the forefront of transforming healthcare practices and addressing critical health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sacramento, California, United States
Patients applied
Trial Officials
Ling Chen, MD
Study Director
UCDavis Transplant Nephrology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials